APA (7th ed.) Citation

A, T., A, P., W, E., B, B., L, B., G, M., . . . EV, S. (2026). An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients. Therapeutic advances in gastroenterology, 19, 17562848261455563. https://doi.org/10.1177/17562848261455563

Chicago Style (17th ed.) Citation

A, Tursi, et al. "An Inverse Probability of Treatment Weighted Comparison Between Vedolizumab, Ustekinumab, and Tofacitinib in Anti-TNF-experienced Ulcerative Colitis Patients." Therapeutic Advances in Gastroenterology 19 (2026): 17562848261455563. https://doi.org/10.1177/17562848261455563.

MLA (9th ed.) Citation

A, Tursi, et al. "An Inverse Probability of Treatment Weighted Comparison Between Vedolizumab, Ustekinumab, and Tofacitinib in Anti-TNF-experienced Ulcerative Colitis Patients." Therapeutic Advances in Gastroenterology, vol. 19, 2026, p. 17562848261455563, https://doi.org/10.1177/17562848261455563.